Interleukin-4 polymorphisms and response to combination therapy in Egyptian chronic hepatitis C patients

Cellular Immunology

Volumn 276, Issue 1-2, 2012, Pages 110-113

  Shalaby, Sally M ^a   Radwan, Mohamed I ^a   Abdelazim, Shymaa ^b   Nafee, Abeer M ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

Hepatitis C virus; Interferon ; Interleukin 4 polymorphism; Ribavirin

Indexed keywords

INTERFERON; INTERLEUKIN 4; RIBAVIRIN;

ADULT; ALLELE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; EGYPT; FEMALE; HAPLOTYPE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ALLELES; ANTIVIRAL AGENTS; DRUG COMBINATIONS; EGYPT; FEMALE; GENETICS, POPULATION; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKIN-4; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 84863876587     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.04.009     Document Type: Article

References (36)

1. Abdel-Hamid M., El-Daly M., Molnegren V., El-Kafrawy S., Abdel-Latif S., Esmat G., Strickland G.T., Loffredo C., Albert J., Widell A. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J. Gen. Virol. 2007, 88:1526-1531.
2. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345:41-52.
3. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 2009, 119:1745-1754.
4. Chung R.T., Andersen J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 2004, 351:451-459.
5. Dalgard O., Bjøro K., Hellum K.B., Myrvang B., Ritland S., Skang K., et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14weeks: a pilot study. Hepatology 2004, 40:1260-1265.
6. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infection with genotype 1 and low pretreatment viremia. J. Hepatol. 2006, 44:97-103.
7. Fainboim L., Cherñavsky A., Paladino N., Flores A.C., Arruvito L. Cytokines and chronic liver disease. Cytokine Growth F. R. 2007, 18:143-157.
8. Ndms K., Keegan A.D., Zamorano J., Ryan J.J., Paul W.E. The IL4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 1999, 17:701-738.
9. Frazer K.A., Ueda Y., Zhu Y., et al. Computational and biological analysis of 680 kb of DNA sequence from the human 5q31 cytokine gene cluster region. Genome Res. 1997, 7:495-512.
10. Vandenbroeck K., Goris A. Cytokine gene polymorphisms in multifactorial diseases: Gateways to novel targets for immunotherapy?. Trends Pharmacol. Sci. 2003, 24:284-289.
11. Morgan T.R., Lambrecht R.W., Bonkovsky H.L., Chung R.T., Naishadham D., Sterling R.K., Fontana R.J., Lee W.M., Ghany M.G., Wright E.C., O' Brien T.R. HALT-C Trial Group. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J. Hepatol. 2008, 49:548-556.
12. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Günthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Müllhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138(el-7):1338-1345.
13. Vidigal P.G., Germer J.J. Zein NN Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J. Hepatol. 2002, 36:271-277.
14. Dogra G., Chakravarti A., Kar P., Chawla Y.K. Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response. Hum. Immunol. 2011, 72:935-939.
15. Saito T., Ji G., Shinzawa H., Okumoto K., Hattori E., Adachi T., Takeda T., Sugahara K., Ito J.I., Watanabe H., Saito K., Togashi H., Ishii K., Matsuura T., Inageda K., Muramatsu M., Kawata S. Genetic variations in humans associated with differences in the course of hepatitis C. Biochem. Biophys. Res. Commun. 2004, 30:335-341.
16. Bedoss P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
17. Noguchi E., Shibasaki M., Arinami T., et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin. Exp. Allergy 1998, 28:449-453.
18. Cabantous S., Poudiougou B., Oumar A.A., Traore A., Barry A., Vitte J., Bongrand P., Marquet S., Doumbo O., Dessein A.J. Genetic evidence for the aggravation of Plasmodium falciparum malaria by interleukin 4. J. Infect. Dis. 2009, 15:1530-1539.
19. Hegab A.E., Sakamoto T., Saitoh W., Massoud H.H., Massoud H.M., Hassanein K.M., Sekizawa K. Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest 2004, 126:1832-1839.
20. Borden E.C., Waalen J., Schreiber R., Williams B. Response and resistance to interferons and interacting cytokines. J. Natl. Cancer I. 1995, 87:257-264.
21. Shapiro S., Gershtein V., Elias N., Zuckerman E., Salman N., Lahat N. MRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment. Clin. Exp. Immunol. 1998, 114:55-60.
22. Furusyo N., Kubo N., Toyoda K., Takeoka H., Nabeshima S., Murata M., Nakamuta M., Hayashi J. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. Antiviral Res. 2005, 67:46-54.
23. Younossi Z.M., Limongi D., Stepanova M., Pierobon M., Afendy A., Mehta R., Baranova A., Liotta L. Petricoin E Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). J. Proteome Res. 2011, 4:774-779.
24. Naslednikova I.O., Konenkov V.I., Ryazantseva N.V., Novitskii V.V., Tkachenko S.B., Zima A.P., Avdoshina V.V., Beloborodova E.I., Beloborodova E.V., Dortman V.V. Role of genetically determined production of immunoregulatory cytokines in immunopathogenesis of chronic viral hepatitides. Bull Exp. Biol. Med. 2007, 143:706-712.
25. Chen T.Y., Hsieh Y.S., Wu T.T., Yang S.F., Wu C.J., Tsay G.J., Chiou H.L. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl. Res. 2007, 150:116-121.
26. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
27. Yee L.J., Tang J., Gibson A.W., Kimberly R., Van Leeuwen D.J., Kaslow R.A. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001, 33:708-712.
28. Chuang J.Y., Yang S.S., Lu Y.T., Hsieh Y.Y., Chen C.Y., Chang S.C., Chang C.S., Yeh H.Z., Kao J.H. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig. Liver Dis. 2009, 41:424-430.
29. Rosenwasser L.J., Klemm D.J., Dresback J.K., et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin. Exp. Allergy 1995, 25(S2):74-78.
30. Wierenga E.A., Messer G. Regulation of interleukin 4 gene transcription: alteration in atopic disease?. Am. J. Respir. Crit. Care Med. 2000, 162:S81-S85.
31. Nakashima H., Miyake K., Inoue Y., et al. Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun. 2002, 3:107-109.
32. Larner A.C., Petricoin E.F., Nakagawa Y., Finbloom D.S. IL-4 attenuates the transcriptional activation of both IFN-alpha and IFN-gamma induced cellular gene expression in monocytes and monocytic cell lines. J. Immunol. 1993, 150:1944-1950.
33. Lohoff M., Marsig E., Rollinghoff M. Murine IL-4 antagonize the protective effects of aIFN on virus mediated lysis of murine L929 fibroblast cells. J. Immunol. 1990, 144:960-963.
34. Nickolaus P., Zawatzky R. Inhibition by IL-4 of constitutive beta-interferon synthesis in mouse macrophages. J. Virol. 1994, 68:6763-6766.
35. Varano B., Fantuzzi L., Puddu P., Borghi P., Belardelli F., Gessani S. Inhibition of the constitutive and induced IFN-B production by IL-4 and IL-10 in murine peritoneal macrophages. Virology 2000, 277:270-277.
36. Sriram U., Biswas C., Behrens E.M., Dinnall J.A., Shivers D.K., Monestier M., Argon Y., Gallucci S. IL-4 suppresses dendritic cell response to type I interferons. J. Immunol. 2007, 15:6446-6455.